For Corporate Acquirers
Identify clinical adoption, manufacturing integration, regulatory alignment, and IP strength in acquisition targets. Quick Score from $2,500 (24h). Corporate Score $25,000 (48h).
Multi-Target Screening
Rank multiple targets — bolt-ons, build-vs-buy candidates, or strategic options — before committing to a single LOI
| Company | Score | Status |
|---|
De-Risk Your Pipeline
Identify and eliminate risk before engagement letters.
What We Find
Clinical adoption as deal risk
Unvalidated integration failure rate
Avg post-close remediation cost
Risk concordance validated
Does the platform roadmap align with target capabilities? We validate technical synergies before integration begins.
Quality, scale, and supplier consolidation risks. We identify design-for-manufacturing gaps before acquisition.
FDA pathway viability and compliance readiness. Hidden regulatory risk = 12-18 month delays and $1-3M remediation.
Patent defensibility and freedom-to-operate. We assess IP quality before integrating into your platform.
Reimbursement alignment and customer overlap. Cross-category pattern intelligence validated across 2,000+ outcomes.
Will clinicians adopt the integrated solution? Workflow disruption kills post-close value faster than technical issues.
Pricing
Rapid due diligence for deal screening. Deep assessments for finalists. Custom engagement for large platforms.
Also available: Annual partnerships for active acquirers. Contact us →
Acquisitions without clinical-technical validation face 3.2x higher failure rates and $4-6M+ in post-close remediation.
Deal Lifecycle
Risk validation from target screening through post-close integration
Quick Score on inbound targets to identify clinical and manufacturing red flags early
Corporate Score with integration planning and board-level recommendations
Strategic DD report with synergy quantification and risk remediation roadmap
Integration checkpoints and close-related Q&A support
Milestone tracking and integration risk surveillance
How we'd diligence a target
We'd rather show you the framework run on cases your corp-dev team already knows than ask you to trust an unnamed testimonial. Each card is a public retrospective with the integration risk our M&A Score would have surfaced pre-LOI.
200K+ implants recalled, Chapter 11 in 2024. The materials-chemistry and complaint-trend signals were knowable; we walk what corp-dev should have asked the QMS team.
Read the retrospective →FDA warning letter forced a category change post-IPO, halting US sales for 18 months. The regulatory exposure was visible in public filings before the deal cycle.
Read the retrospective →First FDA-cleared prescription digital therapeutic, $1.6B SPAC, bankrupt in 24 months. We trace the payer-coverage and prescribing-economics signals available pre-deal.
Read the retrospective →Named corporate engagements remain confidential until the acquirer authorizes attribution. Public retrospectives are how we let buyers verify our framework before signing.
Unlimited assessments, priority support, and quarterly M&A risk briefings. Ideal for platforms with consistent acquisition activity.
Explore Partnership Options →Start with Quick Score to screen inbound opportunities. Engage our team for comprehensive Corporate Score on finalists.
The 20 clinical, manufacturing, and regulatory risks that derail acquisitions. Created by Dr. Arvind Ravinutala (MD) and Aswini Ravinutala (BME).
Download the ChecklistNo email required. No paywall.